When It's Not Mechanical Back Pain: What the PCP Needs to Know
Rheumatology
Curriculum:
Managing Back Pain in the Primary Care Setting: Toward the Timely Recognition and Treatment of AxSpA
Managing Back Pain in the Primary Care Setting: Toward the Timely Recognition and Treatment of AxSpA
Credits:
0.5 AMA PRA Category 1 Credit(s) ™
0.5 AMA PRA Category 1 Credit(s) ™
Launch Date:
April 28, 2016
April 28, 2016
Expiration Date:
The accreditation for this activity has expired.
The accreditation for this activity has expired.
Primary Audience:
The intended audience for the activity is primary care physicians and other health care professionals involved in the treatment of patients with back pain.
Relevant Terms:
AxSpA
Lianne S. Gensler, MD
Lianne S. Gensler, MD
Associate Professor of Clinical Medicine
Director, Ankylosing Spondylitis Clinic
University of California, San Francisco
San Francisco, CA
Bio
Lianne S. Gensler, MD, is an associate professor of medicine and rheumatology at the University of California San Francisco (UCSF), where she is also director of the Ankylosing Spondylitis Clinic. Dr. Gensler completed medical school at the University of California, Irvine and then did her internship, residency, and chief residency at UCSF, where she stayed to complete her fellowship in rheumatology and became faculty thereafter.At UCSF, Dr. Gensler teaches medical students, residents, and fellows and is involved in clinical research in spondyloarthritis, including epidemiologic research and clinical trials. Dr. Gensler is the vice-chair of the Spondyloarthritis Research and Treatment Network (SPARTAN), served on the American College of Rheumatology treatment guidelines for axial spondyloarthritis, and serves in several other educational capacities for the college.
Atul A. Deodhar, MD
Atul A. Deodhar, MD
Professor of Medicine
Medical Director, Rheumatology Clinics
Division of Arthritis & Rheumatic Diseases
Oregon Health & Science University
Portland, OR
Bio
Through his role on the Executive Committee of the SpondyloArthritis Research and Treatment Network (SPARTAN), Dr. Deodhar has been dedicated to spondyloarthritis research, including epidemiology, diagnosis, and treatment strategies. He has been engaged in clinical trials assessing the efficacy of novel therapies in ankylosing spondylitis and psoriatic arthritis. Together with the Department of Dermatology, he has created the Center for Psoriasis and Psoriatic Arthritis Excellence (CEPPA) at OHSU, a multidisciplinary clinic which has provided care for patients with psoriasis and psoriatic arthritis and allowed the collection and analysis of a CEPPA registry. Dr Deodhar has also published in the field of osteoporosis specifically as it relates to inflammatory arthritis and has been interested in the use of hand bone densitometry to monitor progression of inflammatory arthritis. As a fellow, Dr. Deodhar worked with Dr. Robert Bennett on understanding various aspects of fibromyalgia including its diagnosis and treatment. Dr. Deodhar has completed the Train-the-trainer USSONAR course in musculoskeletal ultrasound and is conducting an ultrasound guided injection clinic that fellows attend.Walter P. Maksymowych, MD, FRCP(C), FACP
Walter P. Maksymowych, MD, FRCP(C), FACP
Professor, Department of Medicine
Division of Rheumatology
University of Alberta
Alberta, Canada
Bio
Walter P. Maksymowych, MD, FRCP(C), FACP, is a Professor and Medical Scientist in the Department of Medicine, Division of Rheumatology at the University of Alberta, Alberta, Canada. He is the 2012 recipient of the Distinguished Investigator Award from the Canadian Rheumatology Association. He is also Chair of the International OMERACT Soluble Biomarker Working Group, the Scientific Chair of the Alberta Rheumatoid Arthritis and Pharmacovigilance Program and Outcomes Research in Therapeutics (RAPPORT) committee. He is past-Chair of the Scientific Committee of the Canadian Rheumatology Association. He founded Canadian Research and Education (CaRE) Arthritis Limited, an Alberta company focused on the development of personalized medicine strategies for patients with arthritis, and now serves as Chief Medical Officer.Dr. Maksymowych graduated from the University of Manchester School of Medicine, United Kingdom, in 1981 and completed his postgraduate training at the University of Alberta and the Children's Hospital Medical Center, Cincinnati, Ohio. He holds Fellowships in the Royal College of Physicians of Canada and the American College of Physicians. His primary research interests are the imaging, genetics, and treatment of spondyloarthritis, and the clinical validation of biomarker technologies for rheumatic diseases. He has published over 250 research articles and is a member of numerous international societies related to arthritis research. His research activities involve a global network of investigators and major partners in the pharmaceutical, imaging, and biomarker industries. He has spearheaded numerous international collaborative networks that have culminated in the development of multiple scoring systems based on imaging and biomarker technologies for use in both diagnostic and therapeutic settings as well as clinical trials research. Most recently, he co-invented the 14-3-3 biomarker platform which has recently been licensed for diagnostic testing of patients with rheumatoid arthritis.
| 1. | Identify patients with AxSpA based on symptomatic domains, classification criteria, and established guidelines and refer to a specialist as warranted. | 2. | Utilize appropriate lifestyle and therapeutic interventions for the management of AxSpA. |
| 1. | Identify patients with AxSpA based on symptomatic domains, classification criteria, and established guidelines and refer to a specialist as warranted. |
| 2. | Utilize appropriate lifestyle and therapeutic interventions for the management of AxSpA. |
Provider Statement:
This continuing medical education activity is provided by
Support Statement:
This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.
Credit Information/Accreditation:
This enduring material is approved for 1 year from the date of original release, April 28, 2016 to April 27, 2017.
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation:
Vindico Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material is approved for 1 year from the date of original release, April 28, 2016 to April 27, 2017.
Disclosures:
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears below.
Faculty:
Lianne S. Gensler, MD
Consulting Fee: AbbVie, Amgen, Janssen, Novartis
Contracted Research: UCB
Atul A. Deodhar, MD
Consulting Fee: AbbVie, Boehringer Ingelheim, Janssen, Novartis, Pfizer, Sun Pharma, UCB
Contracted Research: AbbVie, Amgen, Eli-Lilly, Janssen, Novartis, Pfizer
Walter P. Maksymowych, MD, FRCP(C), FACP
Consulting Fee: AbbVie, Amgen, Boehringer Ingelheim, Eli-Lilly, Pfizer, UCB
Contracted Research: AbbVie, Janssen
External Reviewer:
Leonard H. Calabrese, DO
Consulting Fees: GlaxoSmithKline, Janssen, Pfizer, Sanofi
Speakers Bureau: AbbVie, Bristol-Myers Squibb, Crescendo, Genentech, Janssen
Vindico Medical Education staff report the following relationship(s):
No relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Overview:
Back pain is a very common disorder that affects nearly 80% of adults. Back pain can be caused by mechanical damage to the muscles, ligaments, discs, bones, or inflammation. Axial spondyloarthritis (AxSpA) is an autoimmune disease of the axial skeleton, whose classification is dependent upon the presence of inflammatory back pain (IBP). Since x-rays are often insensitive to early disease diagnosis, there can be a significant delay in assessing the etiology and rendering appropriate treatment. In this activity, leading rheumatologists will identify patients with AxSpA based on symptom domains and diagnostic features, discussing the benefits of therapeutic lifestyle changes as well as medical management.
How To Participate in this Activity and Obtain CME Credit:
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, complete the CME posttest, and complete the evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 2 of the 3 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Unlabeled and Investigational Usage:
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.
No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any Vindico Medical Education continuing education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Vindico Medical Education, nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
For downloadable educational resources, visit below.
- Axial spondyloarthritis: is there a treatment of choice?
- What Is Axial Spondyloarthritis (AxSpA)?
- Rheumatologists Make Progress Defining Spectrum of Axial Spondyloarthritis
- Recommendations for the Treatment of Ankylosing Spondylitis
For a full list of all the educational tools available through Vindico Medical Education, please visit www.VindicoCME.com/educationaltools.
Course Viewing Requirements:
| Supported Browsers: Internet Explorer 9.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 Google Chrome 28.0+ for Windows, Mac OS, or Linux Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux Safari 6.0+ for Mac OSX 10.7 and above | Supported Phones & Tablets: Android 4.0.3 and above iPhone/iPad with iOS 6.1 or above |
© 2007-2024 HealthCourse, Inc. All rights reserved.
